CYTK: financial statements from SEC — TradeAlmanac

CYTK

Cytokinetics, Incorporated: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	19m	2m	67m	2m	463,000	249,000
Research and development	96m	99m	113m	100m	85m	80m
Selling, general and administrative	105m	69m	66m	57m	57m	51m
Operating expenses	203m	169m	178m	157m	141m	130m
Operating income	−184m	−167m	−112m	−156m	−141m	−130m
Interest expense	—	11m	11m	—	9m	13m
Net income	−206m	−306m	−134m	−161m	−161m	−143m
Earnings per share	−1.67	−2.55	−1.12	−1.36	−1.36	−1.31
Earnings per share, diluted	−1.67	−2.55	−1.12	−1.36	−1.36	−1.31
Weighted average shares	123,273	119,982	119,457	118,496	117,685	109,240
Weighted average shares, diluted	123,273	119,982	119,457	118,496	117,685	109,240

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	130m	123m	225m	75m	74m	95m	47m	190m
Receivables	7m	18m	2m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−145m	−132m
Depreciation and amortisation	3m	2m
Share-based compensation	30m	24m
Capital expenditure	6m	6m
Investing cash flow	145m	106m
Financing cash flow	8m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)